T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy

Author & Article Information

  • G. Coukos and I. Melero share senior authorship for this article.

    • Corresponding Authors: Ignacio Melero, Center for Applied Medical Research and Clinica Univerisidad de Navarra, Av. Pio XII, 55, 31008 Pamplona, Spain. Phone: 34-948194700; Fax: 34-948194717; E-mail: imelero@unav.es; and George Coukos, Rue du Bugnon 27, CH-1011, Lausanne, Switzerland. E-mail: george.coukos@chuv.ch

  • Online ISSN: 2159-8290

  • Print ISSN: 2159-8274

  • ©2014 American Association for Cancer Research.

Source: Cancer Discov (2014) 4 (5): 522–526. https://doi.org/10.1158/2159-8290.CD-13-0985


Abstract

Cancer immunotherapy has great promise, but is limited by diverse mechanisms used by tumors to prevent sustained antitumor immune responses. Tumors disrupt antigen presentation, T/NK–cell activation, and T/NK–cell homing through soluble and cell-surface mediators, the vasculature, and immunosuppressive cells such as myeloid-derived suppressor cells and regulatory T cells. However, many molecular mechanisms preventing the efficacy of antitumor immunity have been identified and can be disrupted by combination immunotherapy. Here, we examine immunosuppressive mechanisms exploited by tumors and provide insights into the therapies under development to overcome them, focusing on lymphocyte traffic. Cancer Discov; 4(5); 522–6. ©2014 AACR.


See the original article here | American Association for Cancer Research

Previous
Previous

Cancer vaccines: trafficking of tumor-specific T cells to tumor after therapeutic vaccination

Next
Next

Small molecule agonist of very late antigen-4 (VLA-4) integrin induces progenitor cell adhesion